Format

Send to

Choose Destination
Vaccine. 2001 Mar 21;19(17-19):2323-8.

Peptide and recombinant antigens for protection against bacterial middle ear infection.

Author information

1
The Ohio State University College of Medicine and Public Health, Department of Pediatrics, Division of Molecular Medicine, Children's Research Institute, Columbus, OH 43205-2696, USA. bakaletl@pediatrics.ohio-state.edu

Abstract

Passive immunization of chinchillas with serum specific for either LB1 or for LPD-LB1 (f)(2,1,3) prior to challenge with heterologous NTHI isolates (relative to diversity in region three of P5-fimbrin), significantly inhibited the signs and incidence of otitis media (P < or = 0.01) induced by any of the challenge isolates. The ability of these antisera to induce total eradication of NTHI from the nasopharynx was not however equivalent among challenged cohorts. The data thus suggested that while early, complete eradication of NTHI from the nasopharynx was highly protective, reduction of the bacterial load to below a critical threshold level appeared to be similarly effective. Both immunogens thus remain strong vaccine candidates.

PMID:
11257356
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center